Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$637M |
| 2 |
Weyerhaeuser
WY
|
+$340M |
| 3 |
IQVIA
IQV
|
+$132M |
| 4 |
Halliburton
HAL
|
+$123M |
| 5 |
Dover
DOV
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$3.68B |
| 2 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$708M |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$460M |
| 4 |
RAI
Reynolds American Inc
RAI
|
+$293M |
| 5 |
Gilead Sciences
GILD
|
+$246M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Healthcare | 5.12% |
| 3 | Financials | 4.53% |
| 4 | Consumer Discretionary | 4.09% |
| 5 | Communication Services | 3.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IIF
3626
Morgan Stanley India Investment Fund
IIF
$220M
| $477K | ﹤0.01% |
13,922
| – | – |
|
3627
PetMed Express
PETS
$42.1M
| $477K | ﹤0.01% |
14,406
+9,533
| +196% | +$388K |
|
|
NXGN
3628
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $476K | ﹤0.01% |
30,266
+1,338
| +5% | +$21.6K |
|
3629
Sasol
SSL
$7.24B
| $475K | ﹤0.01% |
17,283
+17,209
| +23,255% | +$506K |
|
|
DCPH
3630
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $475K | ﹤0.01% |
+25,000
| New | +$458K |
|
|
JBGS
3631
CALL
JBG SMITH
JBGS
$707M
| $474K | ﹤0.01% |
+13,850
| New | +$469K |
|
3632
CALL
Middleby
MIDD
$6.03B
| $474K | ﹤0.01% |
3,700
+3,500
| +1,750% | +$432K |
|
3633
CALL
Trade Desk
TTD
$8.31B
| $474K | ﹤0.01% |
77,000
+64,000
| +492% | +$346K |
|
|
MDP
3634
DELISTED
Meredith Corporation
MDP
| $474K | ﹤0.01% |
8,534
-26,365
| -76% | -$1.49M |
|
|
MTOR
3635
CALL
DELISTED
MERITOR, Inc.
MTOR
| $473K | ﹤0.01% |
18,200
-900
| -5% | -$17.9K |
|
3636
CALL
iShares Russell 2000 Value ETF
IWN
$14.5B
| $472K | ﹤0.01% |
3,800
+1,900
| +100% | +$224K |
|
3637
Vanguard Health Care ETF
VHT
$18.4B
| $472K | ﹤0.01% |
3,100
| – | – |
|
3638
Lexicon Pharmaceuticals
LXRX
$1.05B
| $471K | ﹤0.01% |
38,371
+8,123
| +27% | +$120K |
|
3639
Arbutus Biopharma
ABUS
$897M
| $470K | ﹤0.01% |
75,741
+2,941
| +4% | +$12.6K |
|
3640
PUT
AGNC Investment
AGNC
$12.6B
| $470K | ﹤0.01% |
21,700
-38,500
| -64% | -$823K |
|
3641
CALL
Alerian MLP ETF
AMLP
$12.9B
| $469K | ﹤0.01% |
8,360
+1,920
| +30% | +$110K |
|
3642
iShares 0-5 Year TIPS Bond ETF
STIP
$15.8B
| $469K | ﹤0.01% |
4,675
| – | – |
|
3643
PUT
SM Energy
SM
$6.88B
| $468K | ﹤0.01% |
26,400
+1,900
| +8% | +$29.7K |
|
3644
Pinnacle Financial Partners Inc
PNFP
$16.1B
| $467K | ﹤0.01% |
6,994
-122,369
| -95% | -$7.71M |
|
|
PRTK
3645
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $466K | ﹤0.01% |
18,553
+3,155
| +20% | +$73.4K |
|
|
XEC
3646
CALL
DELISTED
CIMAREX ENERGY CO
XEC
| $466K | ﹤0.01% |
4,100
-144,600
| -97% | -$14.4M |
|
3647
Heron Therapeutics
HRTX
$94.5M
| $465K | ﹤0.01% |
28,791
+23,426
| +437% | +$367K |
|
3648
PUT
Adient
ADNT
$1.45B
| $464K | ﹤0.01% |
5,529
+4,700
| +567% | +$333K |
|
3649
CALL
iShares US Transportation ETF
IYT
$2.27B
| $464K | ﹤0.01% |
10,400
+10,000
| +2,500% | +$425K |
|
3650
Avient
AVNT
$3.91B
| $462K | ﹤0.01% |
11,530
-2,108
| -15% | -$78.6K |
|
Similar funds
Barclays's Q3 2017 Portfolio in Review
As of Q3 2017, Barclays held 7,380 positions worth $97.1B, up 4% from $93.4B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Barclays's Q3 2017 filing shows 424 new, 3,249 increased, 2,816 reduced and 405 closed positions. Its largest new stake was Crown Castle International Corp. 6.875% Mandatory Convertible Preferred Stock, Series A: 39,656 shares worth $42.4M. The largest sale was Invesco QQQ Trust, an estimated $3.68B.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, up from 6.1% a quarter earlier, followed by Healthcare and Financials.
- Barclays's largest Q3 2017 buy was Crown Castle International Corp. 6.875% Mandatory Convertible Preferred Stock, Series A: 39,656 shares worth $42.4M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q3 2017, an estimated $637M increase.
- Barclays's biggest Q3 2017 reduction was Invesco QQQ Trust, cutting an estimated $3.68B.
- Barclays fully exited Reynolds American Inc in Q3 2017, selling an estimated $293M.
- Barclays's ten largest holdings make up 29% of its $97.1B portfolio in Q3 2017.
- Barclays opened 424 new positions and closed 405 in Q3 2017.
- Barclays's portfolio value rose 4% quarter-over-quarter to $97.1B.
Based on Barclays's 13F filing for Q3 2017, filed 14 Nov 2017.